Malaria Vaccine Development Unit (mvdu)

Saul, Allan

Abstract

Malaria Vaccine Development Unit (MVDU) General Description: The Malaria Vaccine Development Unit (MVDU) is an NIAID initiative in close collaboration with DMID to respond to the global need for vaccines against malaria. We now have produced six cGMP products: AMA1 FVO, AMA1 3D7, MSP1(42) FVO, MSP1(42) 3D7, Pfs25, Pvs25. Three of these antigens (Pvs25H, AMA1-FVO and AMA1-3D7) are in two phase 1 trials (AMA-FVO and AMA1-3D7 as the mixture AMA1-C1) and we are collaborating on the Phase I field testing in Mali of another malaria vaccine, FMP1. We are in the process for completing the IND application for three more antigens (Pfs28, MSP1(42)-FVO and MSP1(42)-3D7). Several other antigens are in the predevelopment Phase. In the past year we have made considerable progress with developming the assays (e.g. in vitro growth inhibtion assays) required to evaluate the outocme of malaria vaccine trials and with our colleages from the University of Mali made considerable progress in developing a field vaccine testing capability and in establishing the baseline epidemiology in which Phase 2 trials will be based.

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Institute of Allergy and Infectious Diseases (NIAID)
• Type: Intramural Research (Z01)
• Project #: 1Z01AI000727-09
• Application #: 6808709
• Study Section: (LPD)
• Support Year: 9
• Fiscal Year: 2003

Institution

• Name: Niaid Extramural Activities
• Country: United States

Publications

Wille-Reece, Ulrike; Flynn, Barbara J; Lore, Karin et al. (2006) Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J Exp Med 203:1249-58

Giersing, Birgitte K; Dubovsky, Filip; Saul, Allan et al. (2006) Potency assay design for adjuvanted recombinant proteins as malaria vaccines. Vaccine 24:4264-70

Trinh, Loc; Phue, Je-Nie; Jaluria, Pratik et al. (2006) Screen-less expanded bed column: new approach for the recovery and purification of a malaria transmission blocking vaccine candidate from Pichia pastoris. Biotechnol Lett 28:951-8

Saxena, Ajay K; Singh, Kavita; Su, Hua-Poo et al. (2006) The essential mosquito-stage P25 and P28 proteins from Plasmodium form tile-like triangular prisms. Nat Struct Mol Biol 13:90-1

Mullen, Gregory E D; Giersing, Birgitte K; Ajose-Popoola, Olubunmi et al. (2006) Enhancement of functional antibody responses to AMA1-C1/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide. Vaccine 24:2497-505

Woehlbier, Ute; Epp, Christian; Kauth, Christian W et al. (2006) Analysis of antibodies directed against merozoite surface protein 1 of the human malaria parasite Plasmodium falciparum. Infect Immun 74:1313-22

Shimp Jr, Richard L; Martin, Laura B; Zhang, Yanling et al. (2006) Production and characterization of clinical grade Escherichia coli derived Plasmodium falciparum 42 kDa merozoite surface protein 1 (MSP1(42)) in the absence of an affinity tag. Protein Expr Purif 50:58-67

Singh, Sanjay; Miura, Kazutoyo; Zhou, Hong et al. (2006) Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity. Infect Immun 74:4573-80

Collins, William E; Barnwell, John W; Sullivan, Joann S et al. (2006) Assessment of transmission-blocking activity of candidate Pvs25 vaccine using gametocytes from chimpanzees. Am J Trop Med Hyg 74:215-21

Tsai, Chiawei W; Duggan, Peter F; Shimp Jr, Richard L et al. (2006) Overproduction of Pichia pastoris or Plasmodium falciparum protein disulfide isomerase affects expression, folding and O-linked glycosylation of a malaria vaccine candidate expressed in P. pastoris. J Biotechnol 121:458-70